Coronavirus Disease among Persons with Sickle Cell Disease, United States, March 20–May 21, 2020

The StudyThe Medical College of Wisconsin established the SECURE-SCD Registry to collect data on COVID-19 cases occurring globally in persons living with SCD.A link to the registry (https://covidsicklecell.org) was distributed to healthcare providers caring for patients with SCD by medical professional and patient advocacy networks and was made available on the Centers for Disease Control and Prevention website.Providers were asked to report all confirmed COV-ID-19 cases among patients with SCD to this registry; they were specifically asked to report only confirmed COVID-19 cases and to report cases after resolution of acute illness or death.Persons who had the sickle cell trait were not included in this registry, nor were persons with SCD who had suspected but not confirmed COVID-19.Providers were asked to report if the patient died of COVID-19 or complications of CO-VID-19.All data were deidentified without protected health information.For each case, providers were asked to complete a short form with questions on demographics; SCD genotype; SCD-related health history; and CO-VID-19 clinical course, severity, and interventions.In addition to data on COVID-19 clinical severity indicators, such as hospitalization, ICU admission, and death, COVID-19 severity level based on patient manifestations were collected by using established criteria for asymptomatic, mild, moderate, severe, and critical (10) (Table ).This analysis was limited to cases among persons with SCD living in the United States reported during March 20-May 21, 2020.We describe the reported cases and deaths caused by COVID-19 and provide Coronavirus Disease among Persons with Sickle Cell Disease, United States,